Advertisement

Der Fokus in der Pädiatrie

  • Josef Peter Guggenbichler
Part of the HNO Praxis heute book series (HNO, volume 26)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Roche Lexikon der Medizin (1993) Fokus/Fokaltoxikose. Urban Schwarzenberg, München Wien Baltimore, S 562Google Scholar
  2. 2.
    Giertz H, Flohe L, Peskar A, Resch K (1992) Mediatoren der Entzündung und Allergie in Pharmakologie und Toxikologie. In: Fort H, Henschler D, Rummel W, Starke K (Hrsg) Allgemeine Pharmakologie und Toxikologie BI Wisenschaftsverlag, Mannheim Leipzig Wien Zürich, S 304–344Google Scholar
  3. 3.
    Milne GL, Musiek ES, Morrow JD (2005) F(2)-Isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers 10Suppl 1: 10–23.CrossRefGoogle Scholar
  4. 4.
    Loesche W, Grossman N (V2001) Periodontal disease as a specific albeit chronic infection. Diagnosis and treatment. Clin Microbiol Rev 727–752Google Scholar
  5. 5.
    Danesh J, Collins R, Peto R (1997) Chronic infection and coronary heart disease. Is there a link? Lancet 350: 430–436PubMedCrossRefGoogle Scholar
  6. 6.
    Buckley RH (2004) Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 5,Suppl A: 225–233CrossRefGoogle Scholar
  7. 7.
    Horn ME, Reed SE, Taylor PE (1979) Role of viruses and bacteria in acute wheezy bronchitis in childhood. A study of sputum. Arch Dis Child 54: 587–592PubMedGoogle Scholar
  8. 8.
    Ring C, Carrol D, Hoving J et al (2005) Effects of competition, exercise, and mental stress on secretory immunity. J Sports Sci 23(5): 501–5088PubMedCrossRefGoogle Scholar
  9. 9.
    Hagashi M. (1994) Adhärenz von Streptococcus pyogenes an Wangenschleimhautepithelien bei Kindern mit rezidivierenden Streoptokokkeninfektionen. Dissertation Univ ErlangenGoogle Scholar
  10. 10.
    Ruder H, Thurn CH, Guggenbichler JP (1992) Adherence of E. coli to uroepithelia in children and adolescents after renal transplantation. Transplant Proc 24: 2576–2577PubMedGoogle Scholar
  11. 11.
    Hagen P, Hobisch A, Guggenbichler JP et al. (1992) Korrelation von vesiko-ureteralem Reflux und rezidivierenden Harnwegsinfektionen mit erhöhter bakterieller Adhärenz. Urologe 31: 186–188PubMedGoogle Scholar
  12. 12.
    Schröder J (1999) Antimikrobielle Peptide — Antibiotika der Zukunft MMP 22: 270–277Google Scholar
  13. 13.
    Brandtzaeg P (1988) Mucosal immunology: with special reference to specific immune defense of upper respiratory tract. Otolaryngology 50: 225–235Google Scholar
  14. 14.
    Benesch KW; Raida M, Mägert HJ et al. (1995) A novel β Defensin from human plasma. FEBS Letter 368: 331–335CrossRefGoogle Scholar
  15. 15.
    Hancock RE (1997) Peptide antibiotics. Lancet 349, 418–422PubMedCrossRefGoogle Scholar
  16. 16.
    Medzhitov R, Janeway C (2000) Innate immune recognition: mechanisms and pathways. Immunol Review 173: 89–97CrossRefGoogle Scholar
  17. 17.
    Medzhitov R (2001) Toll like receptors and innate immunity. Nature Reviews 1: 135–145PubMedCrossRefGoogle Scholar
  18. 18.
    Barton GM, Medzhitov R (2002) Control of adaptive immune responses by Toll like receptors. Curr Opin Immunol 14: 380–383PubMedCrossRefGoogle Scholar
  19. 19.
    Dagan R, Klugman KP, Craig WA, Baquero F (2001) Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimic Chemoth 47: 129–140CrossRefGoogle Scholar
  20. 20.
    Dagan R, Leibovitz E, Greenberg D et al. (1998) Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved outcome. Pediatric Infectious Dis. Journal 17: 778–782Google Scholar
  21. 21.
    Hobermann A, Wald ER, Hickey RW (1999) Oral versus initial intravenous therapy of acute urinary tract infections in young febrile children. Pediatrics 104: 79–86CrossRefGoogle Scholar
  22. 22.
    Guggenbichler JP, Kienel G (1978) Pharmakokinetische Untersuchung mit neuen galenische Zubereitungen von Cephalexin. Päd Pädol 13: 315–320Google Scholar
  23. 23.
    Guggenbichler JP (1982) Resorption oral verabreichter Antibiotika und Chemotherapeutika bei Kindern und ihre Beeinflussung. Päd Pädol 17: 565–584Google Scholar
  24. 24.
    Jürgens, UR, Stöber M, Vetter H (1998) Steroidartige Hemmung des monozytären Arachidonsäuremetabolismus und der IL 1 Produktion durch 1,8-Cineol. Atemw. Lungenkrkh 1: 2–10Google Scholar
  25. 25.
    Cvoriscec B, Ustar M, Pardon R et al. (1989) Oral Immunotherapy of chronic bronchitis: a double blind placebo controlled multicentre study. Respiration 55: 129–135PubMedCrossRefGoogle Scholar
  26. 26.
    Gutierrez-Tarango MD, Berber A (1997) Efficacy of a bacterial extract (OM-85 BV) in preventing recurrent respiratory tract infections in susceptible children. Clin Drug Invest 13: 76–84Google Scholar
  27. 27.
    Maestroni GJ, Losa GA (1984) Clinical and immunobiological effects of an orally administered bacterial extract. Int J Immunopharmacol 111–117Google Scholar
  28. 28.
    Fischer H, Eckenberg P, Van Aubel A et al (1992). Prävention von Infektrezidiven der oberen und unteren Luftwege. Atemw u Lungenkrankh 18: 146–155Google Scholar
  29. 29.
    Wichels M, Wolfschaffner H (1996) Dissertation zur Erlangung des med. Doktorgrades, Univ. Erlangen: Stimulation des sekretions Ig A Systems durch Bakterienlysate und Blockierung der Adhärenz von Mikroorganismen an Schleimhautepithelien. TW Pädiatrie 9: 521–523Google Scholar
  30. 30.
    Maune St, Meyer JE (2001) Potenzial körpereigener antibiotischer Peptide bei der angeborenen Abwehr von Rhinusinusitiden. Allergologie 24: 23–32Google Scholar
  31. 31.
    Mackay I, Rosen F (2000) Innate immunity New Engl J Med 343: 338–344Google Scholar
  32. 32.
    Fleming A (1922) On a remarkable bacteriolytic element founding tissues and secretions. Proc R Soc London 93: 306–317CrossRefGoogle Scholar
  33. 33.
    Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz (1999) Phylogenetic perspectives in innate immunity. Science 284: 1313–1318PubMedCrossRefGoogle Scholar
  34. 34.
    Fulton C, Anderson GM, Stolzenberg Ed et al. (1997) Human β Defensin 1 is a salt sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88: 553–560CrossRefGoogle Scholar
  35. 35.
    Medzhitov R, Janeway CG (2000) Innate Immunity in Advances Immunology. New Engl J Med 338: 338–344CrossRefGoogle Scholar
  36. 36.
    Fan J, Kapuis A, Marsden PA et al. (2002) Regulation of Tolllike receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharides. J Immunology 168: 5252–5259Google Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2006

Authors and Affiliations

  • Josef Peter Guggenbichler
    • 1
  1. 1.Klinik und Poliklinik für Kinder und JugendlicheUniversitätsklinikum ErlangenErlangen

Personalised recommendations